

Claims

1. Use of a therapeutically effective amount of a compound of formula (**I**):



an enantiomer thereof or pharmaceutically acceptable salt of any one of the same, or a composition comprising any one of the same in the manufacture of a medicament, wherein the therapy is continued for 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 months or more.

2. Use according to claim 1, wherein the compound of formula (I) is:



or a pharmaceutically acceptable salt thereof.

3. Use according to claim 1 or 2, wherein the compound of formula (I) is provided as the free base.
4. Use according to any one of claims 1 to 3, wherein the cancer is an epithelial cancer.
5. Use according to any one of claims 1 to 4, wherein the cancer is selected from the comprising liver cancer, biliary tract cancer, breast cancer, prostate cancer, colorectal cancer, ovarian cancer, cervical cancer, lung cancer, gastric cancer, pancreatic, gallbladder cancer, bone cancer, bladder cancer, head and neck cancer, thyroid cancer, skin cancer, renal cancer, and oesophagus cancer.
6. Use according to claim 5, wherein the cancer is selected from gastric cancer, hepatocellular carcinoma and cholangiocarcinoma.
7. Use according to any one of claims 1 to 6, wherein the cancer is HER2 positive or HER2 amplified.
8. Use according to any one of claims 1 to 7, wherein each dose of the compound of formula (I) or composition comprising the same is in the range 100 to 900mg.

9. Use according to claim 8, wherein each dose is in the range of 300 to 500mg.
10. Use according to claim 9, wherein each dose is 400 mg.
11. Use according to any one of claims 1 to 10, wherein the compound of formula (I) or a pharmaceutical composition comprising the same is administered orally.
12. Use according to any one of claims 1 to 11, wherein the compound of formula (I) or a pharmaceutical formulation thereof is administered bi-daily.
13. Use according to any one of claims 1 to 12, wherein the period of cancer remission is prolonged in comparison to a patient population which do not receive a maintenance therapy.
14. Use according to any one of claims 1 to 13, wherein the remission is full remission.
15. Use according to any one of claims 1 to 13, wherein the remission is partial remission.
16. Use according to any one of claims 1 to 13, wherein the patient's life expectancy is increased in comparison to a patient population which do not receive a maintenance therapy.
17. Use according to any one of claims 1 to 16, wherein the patient's creatinine levels are monitored during the period of maintenance therapy.
18. Use according to any one of claims 1 to 16, wherein the dose the compound of formula (I) is reduced in the treatment period.
19. Use according to claim 18, wherein the dose is reduced to be in the range 100 to 300 mg administered once or twice daily.
20. Use according to claim 18 or 19, wherein the dose reduction is in response to an increase in creatinine levels.
21. Use according to claims 17 or 20, wherein the creatinine levels are G3 creatinine levels.